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ess: p.poole@auckland.Summary Background: Patients with chronic obstructive pulmonary disease
(COPD) often report greater relief of breathlessness with nebulised bronchodilators
than with the same medicine administered from a metered dose inhaler (MDI). This
suggests that the nebulised medicines may have an effect on breathlessness over and
above changes in lung function resulting from bronchodilatation.
Methods: Twenty-four subjects with COPD and breathlessness at rest participated
in this randomised, crossover trial. The mean age was 72 years and the mean FEV1
was 26% of predicted. Subjects were studied on four separate days. On two days they
were treated with nebulised salbutamol and on the other 2 days with salbutamol
from an MDI and spacer. With each method of delivery, local anaesthetic cream was
applied to the face on one day and to the back of the hand on the other.
Results: Five minutes after administration of salbutamol the subjects were
significantly less breathless with nebulised salbutamol but by 45min both treatments
resulted in equivalent relief. There was no difference between the treatments in the
change in FEV1 or VC and application of local anaesthetic to the face did not
influence the response.
Conclusion: There was a small early benefit with nebulised salbutamol but this
was not sustained and was not affected by topical anaesthesia. The benefit of
nebulisation does not appear to be large enough to warrant the routine, widespread
use of nebulised bronchodilators for the treatment of stable COPD.
& 2004 Elsevier Ltd. All rights reserved.Introduction
Patients with chronic obstructive pulmonary dis-
ease (COPD) often report relief of breathlessnessElsevier Ltd. All rights reserv
73-7555.
ac.nz (P.J. Poole).when they have cool air blowing on their face. Many
also report greater relief of breathlessness with a
nebulised b2 agonist than they do with the same
medicine administered from a metered dose
inhaler (MDI). A number of studies suggest that
mechanical properties of the nebulisation process
may play a role in the relief of breathlessness. In aed.
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found that nebulised saline reduced breathlessness
almost as much as nebulised terbutaline, even
though saline had no effect on lung function.1 In
another study healthy volunteers experienced less
breathlessness while exercising if a jet of cold air
was directed at the cheek rather than at the leg.2
Patients with COPD have also been shown to
exercise longer, and to report less end-of-exercise
dyspnoea, while breathing air at 7 1C compared
with room temperature.3
The present study was designed to investigate
the effects of nebulisation on breathlessness in
patients with COPD and to answer two questions:(i) Is there a difference in perception of breath-
lessness when a bronchodilator is administered
from a nebuliser compared with delivery of the
bronchodilator administered by via MDI and
spacer?(ii) Is the effect of nebulised bronchodilators on
breathlessness modified by anaesthetising the
face?Methods
Subjects were included in the study if they met the
ATS criteria for a diagnosis of COPD,4 had420 pack-
years smoking history and were breathlessness at
rest. In addition they had to be clinically stable
with no exacerbations in the previous 8 weeks.
Subjects were excluded if they had an FEV1 of
greater than 60% of predicted or if their FEV1
increased by more than 15% and 250ml following
salbutamol. Patients who had heart failure, lung
diseases other than COPD, significant cognitive
impairment, a change in medication in the previous
four weeks, or who were sensitised to local
anaesthetics were also excluded. The study was
approved by the Auckland Ethics Committee and
each subject gave written informed consent.
The subjects were involved in 4 study visits,
within a period of 28 days, with each visit being at
least 2 days apart. At each visit the subjects
received one of the four study treatments (see
Table 1). The treatment order was randomised
using a computer programme in blocks of 24. With
each subject the treatment order was kept in an
opaque, sealed envelope that was opened on the
first study visit.
Subjects were studied at the same time of the
day and under the same conditions. Short-acting
inhaled b2 agonists were withheld for at least 4 h,
long-acting inhaled b2 agonists for at least 12 h, andinhaled ipratropium for at least 6 h prior to each
visit.
Breathlessness was measured using both:(1) A 10 cm Visual Analogue Scale (VAS) with the
term ‘extremely breathless’ at one end and
‘not at all breathless’ at the other.(2) A seven point Likert scale that ranged from
1=‘extremely short of breath’ to 7=’not at all
short of breath’.Likert or category scales are as responsive as VAS
but have less variability,5 and because of the
limited range of responses they have floor and
ceiling effects. For this reason we chose to use both
types of scale.
Lung function was recorded with a dry bellows
spirometer (Vitalograph, Buckingham, UK). The
best of three attempts was used for FEV1 and slow
Vital Capacity.
On arrival at the study centre the subjects rested
for 15min. Following initial recordings, the skin of
the face or hand was cleaned with an alcohol wipe,
and then a local anaesthetic cream of 2.5%
xylocaine and 2.5% prilocaine (EMLA, AstraZeneca
PLC, London, UK) was applied. Thirty minutes (min)
were allowed for the anaesthetic to take effect.
Anaesthesia was determined by loss of skin sensi-
tivity to light touch with a cotton swab. After
further recordings of breathlessness and lung
function, the bronchodilator was administered.
This was either 5mg salbutamol, in a volume of
2.5ml, delivered via a nebuliser (Hospitak, Linden-
hurst, NY, USA) and mask using compressed air at
6 l/min for 5min, or 400mcg of salbutamol, inhaled
one puff (100mcg) at a time, from an MDI and large
volume spacer (Volumatic). Subjects were in-
structed to use tidal breathing while inhaling
salbutamol. The subjects remained seated through-
out the study. Breathlessness was measured again
at 5, 10, 15, 25 and 45min after the start of
administration of salbutamol.
The data was analysed using SAS software (SAS
Institute Inc., Cary, NC, USA), using a mixed
linear model approach. Treatment was entered as
two variables. One variable was whether the
salbutamol was delivered by nebulisation or by
metered dose inhaler. The other was whether or
not EMLA cream was used on the face. Also
included in the model was the order of the
treatment. Baseline recordings were those taken
just prior to salbutamol administration. The five
subsequent readings were analysed as repeated
measures and the subject as a random effect. For
FEV1 and VC there was only one follow-up measure
at 45min.
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Figure 1 Mean change from baseline breathlessness
measured on VAS with salbutamol administered either
by nebuliser or MDI inhaler with spacer. Treatment was
administered between 0 and 5min. Error bars denote
standard errors of the mean.
Table 1 The four study treatments administered in random order.
1 Nebulised salbutamol 5mg +local anaesthetic face
2 Nebulised salbutamol 5mg +local anaesthetic hand
3 Inhaled salbutamol 4 100mcg puffs +local anaesthetic face
4 Inhaled salbutamol 4 100mcg puffs +local anaesthetic hand
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There were 24 subjects (16 male) who completed
all four days of the study. They had a mean age of
72 (SD 6.64, range 57–83) years, a mean smoking
history of 52.5 (27.56) pack-years, and their mean
FEV1 was 0.66 (0.38) l, which was 25.9% (14.50) of
predicted. All subjects had an FEV1o60% of
predicted. On average, the time from the diagnosis
of COPD was 8.6 (5.24) years. Four further subjects
were excluded after randomisation, three when it
was clear on the first or second study day that they
were not short of breath at rest, and one who had
reversibility of 350mls (24%).
Visual analogue scale
Applying the local anaesthetic cream to the face
had no effect on the change in breathlessness over
time as measured on the VAS (P ¼ 0:90) so the use
of anaesthetic cream was removed as a variable
from the analysis.
A difference was observed in the change in the
VAS score over time when nebulised salbutamol was
compared with salbutamol from MDI and spacer
(Fig. 1). When the individual time points were
examined, the VAS scores 5min after treatment
were significantly higher with nebulised salbutamol
(P ¼ 0:0006) than with MDI and spacer. This
difference had disappeared by 45min (P ¼ 0:36).
The mean improvement in VAS 5min after the
administration of salbutamol was 1.04 cm with
nebuliser and 0.47 cm with MDI.
At 45min, however, there was no difference with
mean improvements of 1.30 cm with nebuliser and
1.25 cm with MDI.
Likert score
Similar effects were found when breathlessness was
measured using the Likert score. There was no
effect of applying the local anaesthetic cream to
the face on breathlessness over time (P ¼ 0:56).
The Likert scores at 5min after treatment were
significantly higher with nebulisation than with the
MDI (P ¼ 0:0002). At 5min the mean improvementwas 0.52 points with nebuliser and 0.02 points with
MDI. At 45min, however, there was no difference
with a change of 0.83 points with nebuliser and
0.88 points with MDI (P ¼ 0:92).
There was no difference between nebulised
salbutamol and salbutamol from MDI and spacer in
the FEV1 measured at 45min (P ¼ 0:58). The mean
improvement in FEV1 was 0.12 l (0.1) with nebuliser
and 0.11 l (0.1) with MDI. The FEV1 was not
influenced by the presence or absence of local
anaesthetic cream (P ¼ 0:54). VAS, Likert and FEV1
were not affected by the order in which the
treatments were given.Discussion
We found that 5mg of nebulised salbutamol
provided more rapid initial relief of breathlessness
in subjects with COPD than 400 mg salbutamol, from
an MDI and spacer, but that there was no difference
in breathlessness scores at 45min between the two
modes of delivery. This suggests that the difference
in the initial response to the treatment may be
related to the process of nebulisation. The mean
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point Likert scale. These differences are small but
likely to be clinically significant. In a study of
patients with acute asthma, a change in VAS of at
least 5mm reliably discriminated between those
with and without symptom improvement.6 The
additional benefit seen with nebulisation could be
the result of having a wet aerosol sprayed on to the
face. If so, this could act by cooling the face or
through another neurally mediated mechanism.
Having said this we would have expected the local
anaesthetic cream to reduce the effects of neb-
ulisation and we did not observe this.
Some subjects reported that the moistening and
cooling effect that the nebulisation had on their
nose and throat was comforting. This may have
contributed to the relief of breathlessness. This
effect would not have been modified by the local
anaesthetic which was only applied to the face.
Other studies provide support for this idea. In a
study of patients with terminal cancer and breath-
lessness, the effects of administering oxygen
through nasal prongs was compared with air
delivered at the same rate through nasal prongs.
Air was as effective as oxygen in reducing breath-
lessness.7 In another study where oxygen was
administered through nasal cannulae to patients
with COPD, there was a significant increase in
breathlessness following nasal anaesthesia with
topical lignocaine. This suggests that the reduction
of breathlessness was due to the flow of gas the
nose and not to the increased arterial oxygen
tension.8
Some of our subjects thought that their breathing
was more controlled and regular with nebulisation
than with the MDI and spacer. It is conceivable that
nebulisation does alter the pattern of respiration.
In infants, pressure of a mask in the trigeminal
nerve distribution reduced ventilatory frequency9
but other factors such as noise may play a role. The
importance of dynamic hyperinflation and its
relationship to breathlessness, especially on ex-
ercise, is increasingly being recognised.10 In severe
COPD a slower breathing rate could result in more
efficient expiration of trapped air and improve
symptoms. Despite instructions to the patients to
use tidal breathing, we cannot exclude the possi-
bility that a difference in breathing pattern
accounted for the early benefit of nebulisation.
Another possible explanation for our findings is
that the high dose of salbutamol, delivered by
nebulisation, led to a more rapid improvement in
lung function and this, in turn, led to more rapid
relief of breathlessness, but we think that this is
unlikely to be the case. Although we did not
measure FEV1 and VC over the first 15min of thestudy, other investigators have made serial mea-
surements of FEV1 and VC in subjects with COPD
following inhalation of different doses of salbuta-
mol. Vathanen et al. compared 400 mg, 1, 2 and
4mg of inhaled salbutamol delivered from a dry
powder inhaler in subjects with stable COPD. FEV1
was measured at 2, 5 and 10min after inhaled
salbutamol and at subsequent time points out to
6 h.11 There was no difference in the FEV1 at the
early time points for any of the doses although the
higher doses led to more sustained bronchodilation
at 4 h. Hansen compared the effects of 2mg of
terbutaline from a turbuhaler and 5mg terbutaline
from a jet nebuliser (Pari Inhalierboy) in 22
subjects with stable COPD.12 Changes in FEV1 at 5
and 15min after inhaled terbutaline were the same
for the two treatments. In this study the dose of
terbutaline delivered from the dry powder inhaler
was similar to that from the nebuliser but the study
does illustrate that the process of nebulisation does
not in itself lead to a more rapid improvement in
lung function. Another study compared the effects
of nebulised salbutamol with salbutamol from an
MDI and spacer in the treatment of acute exacer-
bations of COPD. Patients were randomised to
receive three doses of 200mcg salbutamol from
an MDI and spacer (in addition to nebulised saline)
or 2.5mg salbutamol via nebuliser (plus placebo
MDI) over 15min. There was no difference in lung
function between the treatments at any of the
three time points up to 15min.13 None of these
studies suggest that the more rapid improvement in
breathlessness seen with nebulised salbutamol is
likely to be due to an effect on lung function.
A potential weakness of our study is that it was
not blinded, but the different delivery mechanisms
meant it was not possible to conduct a double-blind
study. We could not use a double-dummy design
because nebulised saline can also reduce breath-
lessness.1 The patients were not nebuliser naı¨ve, so
it could be argued that they may have had an
anticipatory response leading to a more rapid
improvement in the breathlessness scores with
nebulisation. To minimise this possible bias, sub-
jects were not made aware of the treatment
allocation until immediately before administration,
and the three investigators who made patient
recordings (RS, SB, PP) kept the study conditions
as similar as possible in all other respects. None-
theless we cannot rule out this possibility alto-
gether.
Nebuliser therapy is used in the community by
many patients with severe COPD. We have pre-
viously found that 40% of patients admitted to our
hospital with an exacerbation of COPD were using
nebulised bronchodilators at home.14 There are,
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cost of the machine and the medication, the lack of
portability, and need to clean and maintain the
machine. Despite the prompt, and clinically sig-
nificant improvement in breathlessness with neb-
ulised salbutamol, this was not sustained and there
was no difference between the treatment groups in
their perception of breathlessness at 45min. The
short-lived difference between treatments in their
effect on breathlessness would not appear suffi-
cient to justify the widespread, routine use of
nebulised bronchodilators in subjects with stable
COPD. Eiser and her colleagues conducted a study
that was of longer duration and came to a similar
conclusion. They studied 19 patients in a cross over
study comparing nebulised bronchodilators with
bronchodilators from MDI and spacer.15 Each treat-
ment was administered four times a day for 2
weeks. There were no significant differences
between the treatments in dyspnoea or quality of
life scores.
We do not believe that our findings should lead to
changes in the current recommendations on the
domiciliary use of nebulised bronchodilators for
patients with stable COPD. However our findings do
support the use of nebulised bronchodilators as
opposed to MDI (plus spacer) in acute exacerbations
where rapid relief of breathlessness is important. It
is still not clear, however, why there is greater
initial benefit with nebulised bronchodilators com-
pared with the use of an MDI and spacer and this
warrants further investigation.Acknowledgements
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